Google
HOWL Stock Price & Analysis — Werewolf Therapeutics Inc (Healthcare >> Biotechnology)
HOWL FAQ
What is HOWL's P/E ratio?
Werewolf Therapeutics Inc (HOWL) currently trades at a P/E ratio of 4.68.
What is HOWL's ROE?
Werewolf Therapeutics Inc reports a Return on Equity (ROE) of -212.45%.
What is HOWL's dividend yield?
Werewolf Therapeutics Inc offers a dividend yield of 0.00%.
What is HOWL's Quality Score?
Our AI rates HOWL's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy HOWL?
Our AI Timing Score for HOWL is 51 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does HOWL belong to?
Werewolf Therapeutics Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
HOWL AI Analysis Summary
Our AI summary for HOWL: Werewolf Therapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 4.68, ROE of -212.45%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 51/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.37
Price
0.01
(4.11%)
Day Change
|
|
|---|
HOWL, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 91 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.37 |
| PBV / Sector |
1.05 / 44,219.29
GREAT
|
| Earning Per Share | -0.74 |
| PE / Sector |
4.68 / 19.28
GREAT
|
| PEG or PE/Growth / Sector |
-1.96 / 1.23
|
| Average 1M Daily Value |
0.33 M
GREAT
|
| Average 1W Daily Value |
0.42 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
47% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-04 08:01:39 |
| Symbol | HOWL |
| Name | WEREWOLF THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 48.60 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 17.16 / 9,645.64 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 200 Talcott Ave, Watertown, MA, United States, 02472
Phone: 617 952 0555
Website: https://werewolftx.com
Sector: Healthcare >> Biotechnology
Description: Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap